At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
COVSurf Drug Delivery System +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19
University Hospital Southampton NHS Foundation Trust·interventional·Posted Apr 24, 2020·Updated Sep 29, 2023
In Brief
A clinical study evaluating COVSurf Drug Delivery System and Standard of Care for Respiratory Infections. Completed, enrolled 20 participants across 2 sites.
Detailed Summary
Lung surfactant is present in the lungs. It covers the alveolar surface where it reduces the work of breathing and prevents the lungs from collapsing. In some respiratory diseases and in patients that require ventilation this substance does not function normally. This study will introduce surfactant to the patients lungs via the COVSurf Drug Delivery System
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Infections
CountriesUnited Kingdom
CollaboratorsBill and Melinda Gates Foundation, University College, London
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartJun 2020
Primary CompletionNov 2022
Study CompletionJan 2023
TodayJul 2026
First PostedApr 24, 2020
Enrollment StartJun 18, 2020
Primary CompletionNov 30, 2022
Study CompletionJan 30, 2023
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 6.2 years ago
Interventions
COVSurf Drug Delivery Systemdevice
Device introduces surfactant to the patients lungs
Standard of Careother
Standard of care treatment for respiratory illness